您好,欢迎来到试剂信息网! [登录] [免费注册]
试剂信息网
位置:首页 > 产品库 > Entacapone-d10
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
Entacapone-d10
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
Entacapone-d10图片
CAS NO:1185241-19-3
包装与价格:
包装价格(元)
500 μg电议
1mg电议

产品介绍
Entacapone-d10 是氘标记的 Entacapone。
Cas No.1185241-19-3
别名恩他卡朋 d10
Canonical SMILESN#C/C(=C\c1cc(O)c(O)c(c1)[N+](=O)[O-])/C(=O)N(C([2H])([2H])C([2H])([2H])[2H])C([2H])([2H])C([2H])([2H])[2H]
分子式C14H5D10N3O5
分子量315.4
溶解度DMSO: Slightly soluble,Methanol: Slightly soluble
储存条件Store at -20°C
General tipsFor obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.
Shipping ConditionEvaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request
产品描述

Entacapone-d10is intended for use as an internal standard for the quantification of entacapone by GC- or LC-MS. Entacapone is a reversible catechol O-methyltransferase (COMT) inhibitor (IC50s = 10, 10, 20, and 160 nM for rat duodenum, brain, erythrocyte, and liver COMT, respectively).1It is selective for COMT over monoamine oxidase A (MAO-A) and MAO-B and phenolsulphotransferase M (PST-M) and PST-P (IC50s = >50 µM). Entacapone (10 mg/kg), in combination with L-DOPA and carbidopa , reduces 3-O-methyldopa (3-OMD) levels in the rat striatum and hypothalamus to 52 and 27%, respectively, of the levels in control animals receiving only L-DOPA and carbidopa.2In a 6-OHDA rat model of Parkinson's disease, entacapone (10 mg/kg), in combination with L-DOPA and benserazide , increases contralateral turning behavior and striatal extracellular dopamine levels.3Entacapone also inhibits contraction of colon longitudinal muscle explants from a 6-OHDA rat model of Parkinson's disease (EC50= 200 µM).4Formulations containing entacapone have been used in the treatment of Parkinson's disease.

1.Nissinen, E., LindÉn, I.B., Schultz, E., et al.Biochemical and pharmacological properties of a peripherally acting catechol-O-methyltransferase inhibitor entacaponeNaunyn Schmiedebergs Arch. Pharmacol.346(3)262-266(1992) 2.MÄnnistÖ, P.T., Tuomainen, P., and Tuominen, R.K.Different in vivo properties of three new inhibitors of catechol O-methyltransferase in the ratBr. J. Pharmacol.105(3)569-574(1992) 3.Gerlach, M., van den Buuse, M., Blaha, C., et al.Entacapone increases and prolongs the central effects of L-DOPA in the 6-hydroxydopamine-lesioned ratNaunyn Schmiedebergs Arch. Pharmacol.370(5)388-394(2004) 4.Li, L.-S., Liu, C.-Z., Xu, J.-D., et al.Effect of entacapone on colon motility and ion transport in a rat model of Parkinson's diseaseWorld J. Gastroenterol.21(12)3509-3518(2015)